Sector News

Pamplona Capital to take Parexel private for $4.5 billion

June 20, 2017
Life sciences

U.S. pharmaceutical research services provider Parexel International Corp said on Tuesday it would be taken private by Pamplona Capital Management LLP in a $4.5 billion deal.

Activist investors, including Starboard Value LP, have put pressure on Parexel to explore a sale, arguing that the company’s profit margins have consistently lagged those of its peers.

Pamplona will pay $88.10 per share in cash for Parexel, representing a 5 percent premium to the stock’s Monday close. Parexel’s shares were trading at $87.67 before the bell, just shy of the offer price.

The stock has jumped more than 20 percent since the first report of a potential sale appeared in May.

Including debt, the deal is valued at $5 billion.

Headquartered near Boston, Massachusetts, Parexel provides a range of services to the pharmaceutical industry, ranging from drug development and regulatory consulting to clinical pharmacology, clinical trials management and reimbursement.

The company focuses on cancer drug research and has a platform for so-called “real-world” data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

Pamplona had been scouring the market in the last year, seeking to acquire a contract research organization. It made an unsuccessful bid earlier this year for Pharmaceutical Product Development LLC (PPD), a U.S. clinical trials firm valued at more than $9 billion.

The contract research industry has been undergoing a wave of consolidation as pharmaceutical companies cut costs, reduce clinical trial times and expand their research and development presence around the world.

Deal-making also allows companies to profit from economies of scale, as they seek to boost their real-world data gathering capabilities.

Last month, INC Research Holdings Inc agreed to merge with inVentiv Health Inc in a $4.6 billion deal. Contract researcher Quintiles Transnational Holdings Inc completed a $9 billion merger with IMS Health Holdings Inc last year.

The Parexel deal is expected to close in the fourth quarter.

Goldman Sachs is Parexel’s financial adviser, while Goodwin Procter LLP served as legal adviser. Perella Weinberg Partners LP Pamplona’s financial adviser, while Kirkland & Ellis LLP is their legal adviser.

By Carl O’Donnell in New York

Source: Reuters

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.